July 23, 2016 7:49 PM ET

Pharmaceuticals

Company Overview of Paddock Laboratories, LLC.

Company Overview

Paddock Laboratories, LLC. a pharmaceutical company, engages in the manufacture, distribution, and marketing of bioequivalent generic pharmaceuticals. The company also provides contract manufacturing services for over the counter and prescription pharmaceutical products in various dosage forms, such as compounding, ophthalmic/OTICS, topical, indictable, liquids/solids, orals, semi-solids, powders, tablets, capsules, enemas, and suppositories. In addition, it offers primary and secondary packaging services and controlled substances, as well as various support services. The company markets its products through distribution partners to retail pharmacies, as well as to institutional customers in...

3940 Quebec Avenue North

Minneapolis, MN 55427

United States

Founded in 1977

Phone:

763-546-4676

Fax:

763-546-4842

Key Executives for Paddock Laboratories, LLC.

Chief Executive Officer and President
Age: 53
Founder and Chairman
Director of Human Resources
Vice President of Business Development
Compensation as of Fiscal Year 2016.

Paddock Laboratories, LLC. Key Developments

Horizon Pharma plc Enters Settlement and License Agreement with Perrigo Company plc and Paddock Laboratories, LLC

Horizon Pharma plc announced that its affiliates have entered into a settlement and license agreement with Perrigo Company plc and its subsidiary Paddock Laboratories, LLC, collectively (Perrigo), to resolve pending patent litigation involving PENNSAID(r) (diclofenac sodium topical solution) 2% w/w (PENNSAID(r) 2%). Under the settlement and license agreement, Horizon has granted Perrigo the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under Perrigo's Abbreviated New Drug Application (ANDA), beginning January 10, 2029 or earlier under certain circumstances. The agreement includes a stipulation by the parties requesting dismissal without prejudice of the lawsuits filed by Horizon in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Delaware relating to the ANDA filed by Perrigo with the U.S. Food and Drug Administration for a generic version of PENNSAID 2%. Details of the settlement are confidential and the agreement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Paddock Laboratories, LLC., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.